Back to Search
Start Over
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
- Source :
-
Journal of inorganic biochemistry [J Inorg Biochem] 2020 Jul; Vol. 208, pp. 111079. Date of Electronic Publication: 2020 Mar 28. - Publication Year :
- 2020
-
Abstract
- The antiproliferative properties of a series of structurally-related gold(I) and silver(I) linear complexes inspired to the clinically established gold-based drug auranofin were investigated in A2780 ovarian cancer cells and in their auranofin (A2780/AF-R) and cisplatin (A2780/CDDP-R) resistant counterparts. In A2780 cells and in the cisplatin-resistant subline, gold-based analogues manifested a cytotoxicity profile comparable or superior to auranofin, while the silver-based analogues were less active; both gold and silver complexes overcame cisplatin resistance. Yet, a high degree of cross resistance toward gold analogues was noticed in A2780/AF-R cells. In the same cell line cross-resistance for silver analogues was also observed, though lower. All metal complexes were scrutinized for their ability to inhibit thioredoxin reductase (TrxR), the putative primary target for auranofin: overall, gold compounds were more potent TrxR inhibitors than the corresponding silver compounds, probably, as the consequence of the stronger binding of gold to the active site selenocysteine residue. These results highlight that the thiosugar ligand of auranofin is not essential for cytotoxicity while the nature of the metal center (gold/silver) plays a relevant role in its modulation. In addition, a rather clear correlation was found between cytotoxic potency of tested compounds and their ability to inhibit TrxR activity, being gold compounds more effective than silver analogues. However, the residual TrxR activity, measured in A2780 cells treated with the half-maximal inhibitory concentrations of various metal complexes, resulted far higher than expected. These results suggest that additional cytotoxic mechanisms must be operative. The implications of these results are discussed.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Cell Line, Tumor
Female
Humans
Structure-Activity Relationship
Antineoplastic Agents chemical synthesis
Antineoplastic Agents chemistry
Antineoplastic Agents pharmacology
Auranofin analogs & derivatives
Auranofin chemical synthesis
Auranofin chemistry
Auranofin pharmacology
Cell Proliferation drug effects
Enzyme Inhibitors chemical synthesis
Enzyme Inhibitors chemistry
Enzyme Inhibitors pharmacology
Neoplasm Proteins antagonists & inhibitors
Neoplasm Proteins metabolism
Ovarian Neoplasms drug therapy
Ovarian Neoplasms enzymology
Ovarian Neoplasms pathology
Thioredoxin-Disulfide Reductase antagonists & inhibitors
Thioredoxin-Disulfide Reductase metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-3344
- Volume :
- 208
- Database :
- MEDLINE
- Journal :
- Journal of inorganic biochemistry
- Publication Type :
- Academic Journal
- Accession number :
- 32497830
- Full Text :
- https://doi.org/10.1016/j.jinorgbio.2020.111079